We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03874052
Recruitment Status : Active, not recruiting
First Posted : March 14, 2019
Last Update Posted : August 12, 2022
Incyte Corporation
Oregon Health and Science University
Information provided by (Responsible Party):
Brian Druker, OHSU Knight Cancer Institute

Brief Summary:
This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or has not responded to treatment (refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. This study is being done to see if the combination of ruxolitinib and venetoclax works better in treating patients with acute myeloid leukemia compared to standard of care chemotherapy.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Drug: Ruxolitinib Drug: Venetoclax Phase 1

Detailed Description:


I. To evaluate the maximum-tolerated dose (MTD) and assess the safety of ruxolitinib in combination with venetoclax.


I. To assess the preliminary efficacy of the ruxolitinib and venetoclax combination.

II. To estimate overall and event-free survival.


I. To assess in vitro kinase inhibitor sensitivity using patient bone marrow (or peripheral blood) before and after treatment with the ruxolitinib and venetoclax combination.

II. To use molecular techniques (potentially including next-generation sequencing and/or BH3 profiling) to examine the mechanisms of response versus (vs.) no response.

III. To correlate molecular features with the patient response and resistance to venetoclax combination therapies.

IV. To determine the pharmacokinetic/pharmacodynamic (PK/PD) concentrations in vivo of the dual drug combination therapy.

OUTLINE: This is a dose-escalation study of ruxolitinib.

Patients receive ruxolitinib orally (PO) twice daily (BID) and venetoclax PO once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.

After completion of study treatment, patients are followed up every 6 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Actual Study Start Date : August 16, 2019
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : December 31, 2023

Arm Intervention/treatment
Experimental: Treatment (ruxolitinib, venetoclax)
Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
Drug: Ruxolitinib
Given PO
Other Names:
  • INCB-18424
  • INCB18424
  • Jakafi
  • Oral JAK Inhibitor INCB18424

Drug: Venetoclax
Given PO
Other Names:
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclexta
  • Venclyxto

Primary Outcome Measures :
  1. Dose-limiting toxicities (DLT) of ruxolitinib and venetoclax in combination [ Time Frame: Up to day 56 ]
    The maximum-tolerated dose (MTD) of ruxolitinib and venetoclax combination will be determined according to the "keyboard" Bayesian toxicity probability interval design. The MTD of the ruxolitinib and venetoclax combination will correspond to the dose level closest to the target DLT probability of 30% and will be estimated from observed dose level-specific DLT rates using isotonic regression. The study will start at dose level 0 with a potential escalation/de-escalation decision occurring for each subsequent cohort of 3 enrolled participants according to the predefined keyboard rules until a dose level has been assigned to all 30 subjects.

Secondary Outcome Measures :
  1. Composite complete remission rate [ Time Frame: From first dose to end of cycle 2 (up to 36 days) ]
    Will be estimated, along with 95% confidence intervals.

  2. Clinical benefit rate (CBR) [ Time Frame: From first dose to end of cycle 2 (up to 36 days) ]
    The clinical benefit rate (CBR) is defined as the proportion of evaluable subjects obtaining stable disease (SD), partial remission (PR), or composite complete remission (CCR) during the first 2 cycles of therapy. Will be estimated, along with 95% confidence intervals.

  3. Event-free survival [ Time Frame: From first dose to end of treatment, relapse from >= partial response (PR), disease progression, or death (whichever occurs first), or date of last exam, assessed up to 12 months ]
    Kaplan-Meier method will be used to estimate and plot event-free survival.

  4. Overall survival [ Time Frame: From date of first dose to death or date of last known alive, assessed up to 12 months ]
    Kaplan-Meier method will be used to estimate and plot overall survival.

  5. Overall incidence of treatment-related and non-treatment related toxicity [ Time Frame: From first dose to 30 days after last dose of study agent ]
    The overall incidence of treatment- related and non-treatment- related toxicity will be determined using the safety-evaluable population. The point estimate and 95% confidence interval for the proportion of patients with each of these toxicity types will be reported. Each toxicity event (there can be > 1 event per participant) will be tabulated by dose level and summarized by severity and major organ site according to the Common Terminology Criteria for Adverse Events version 5.0.

  6. Duration of response [ Time Frame: From first PR or better to loss of best response, or date of last assessment (up to 24 months) ]
    Cumulative incidence functions will be applied to the "competing risks" of the duration of response endpoint, namely, loss of best response and non-relapse death.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to understand and the willingness to sign a written informed consent document
  • Age >= 18 years at time of informed consent. Both men and women and members of all races and ethnic groups will be included
  • Morphologically documented relapsed/refractory acute myeloid leukemia (AML) as defined by World Health Organization (WHO) criteria after at least 1 prior therapy for AML with the exception of hydroxyurea. Patients with myelodysplastic syndrome (MDS) transformed to AML that have been treated with hypomethylating agents may be considered if they fulfill one or more of the following criteria: 1) patient has a left ventricular ejection fraction of 45% or less; 2) patient has a serum creatinine of >= 1.4 gm/dl; 3) patient is age 75 or older
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Women must not be pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration
  • Participants must agree to use an adequate method of contraception
  • Must be able to take oral medications
  • Creatinine clearance >= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection
  • Total serum bilirubin =< 1.5 x upper limit of normal (ULN) unless thought to be due to leukemic involvement
  • Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 3.0 x ULN unless thought to be due to leukemic involvement

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype)
  • Active central nervous system involvement with AML
  • Concurrent active malignancy with expected survival of less than 1 year. For example, candidates with treated skin cancers, prostate cancer, breast cancer, etc. without metastatic disease are candidates for therapy since their expected survival exceeds that of relapsed or refractory AML. All subjects with concurrent malignancies will be reviewed by the principal investigator (PI) prior to enrollment
  • Clinically significant graft versus host disease (GVHD) or active GVHD requiring initiation or escalation of treatment within 28 day screening period
  • Participants with rapidly progressive disease (defined by blast count doubles within 48 hours) or organ dysfunction
  • Clinically significant coagulation abnormality, such as disseminated intravascular coagulation
  • Participants who are currently receiving any other investigational agents
  • Known clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis
  • Untreated human immunodeficiency virus (HIV) or active hepatitis C detectable by polymerase chain reaction (PCR), or chronic hepatitis B (patients positive for hepatitis B core antibody who are receiving intravenous immunoglobulin [IVIG] are eligible if hepatitis [Hep]B PCR is negative)
  • Known history of cerebrovascular accident, myocardial infarction, or intracranial hemorrhage within 2 months of enrollment
  • Clinically significant surgery within 2 weeks of enrollment
  • Per PI discretion, active infection that is not well controlled by antibacterial or antiviral therapy

    • Participants with known history of tuberculosis (TB; Mycobacterium tuberculosis) are not eligible for participation. At investigator discretion, latent TB test should be performed for individuals considered to be at high-risk (e.g., immune compromised, persons that have traveled to, or emigrated from, regions with high rates of TB)
  • Cancer-directed therapy within 1 week prior to starting treatment, with the exception of hydroxyurea, which is allowed to control white blood cell count
  • Unwillingness to receive infusion of blood products
  • Participant on any of the following therapies need to be discussed with the sponsor investigator:

    • Strong and moderate CYP3A inhibitors
    • Strong and moderate CYP3A inducers
  • Patients with uncontrolled white blood cell count (defined as > 50 K/mm^3 not controlled with hydroxyurea)
  • Patients with known sensitivity to ruxolitinib or venetoclax

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03874052

Layout table for location information
United States, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
United States, Oregon
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239
United States, Texas
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Brian Druker
Incyte Corporation
Oregon Health and Science University
Layout table for investigator information
Principal Investigator: Jennifer Saultz, MD OHSU Knight Cancer Institute
Layout table for additonal information
Responsible Party: Brian Druker, IND Holder, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier: NCT03874052    
Other Study ID Numbers: STUDY00018238
NCI-2019-03272 ( Registry Identifier: CTRP (Clinical Trial Reporting Program)] )
STUDY00018238 ( Other Identifier: OHSU Knight Cancer Institute )
First Posted: March 14, 2019    Key Record Dates
Last Update Posted: August 12, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Janus Kinase Inhibitors
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action